Shedding Light on the Molecular Diversities of miRNA in Cancer- an Exquisite Mini Review.
1/5 보강
Short non-coding ribonucleic acids are also known as "Micro ribonucleic acids (miRNAs)".
APA
Venkatesh S, Manaz PM, et al. (2025). Shedding Light on the Molecular Diversities of miRNA in Cancer- an Exquisite Mini Review.. Molecular biotechnology, 67(11), 4025-4037. https://doi.org/10.1007/s12033-024-01312-5
MLA
Venkatesh S, et al.. "Shedding Light on the Molecular Diversities of miRNA in Cancer- an Exquisite Mini Review.." Molecular biotechnology, vol. 67, no. 11, 2025, pp. 4025-4037.
PMID
39496855 ↗
Abstract 한글 요약
Short non-coding ribonucleic acids are also known as "Micro ribonucleic acids (miRNAs)". The miRNAs make a contribution to the regulation of genes and mitigation of cancer cell growth in humans. miRNAs play a significant role in several BPs, namely apoptosis, cell cycle progression, and development. It is well-recognized that miRNAs are crucial for the tumors' growth and also serve as Tumor Suppressors (TSs) or oncogenes. As miRNAs also act as an effective tumor suppressor, studying the molecular diversities of the miRNAs makes way to minimize cancer progression and the corresponding death rates in the future. Therefore, miRNAs along with their Biological Processes (BPs) and molecular diversities are thoroughly researched in this paper. Consequently, miRNAs particularly target their 3' UnTranslated Region (3'-UTR) for controlling the target mRNAs' stability and protein translation. So, this study also expresses the impact of microRNA variants in various cancer cells, namely Breast cancer, Gastric or stomach cancer, ovarian cancer, and lymphocytic leukemia. Furthermore, the database named PhenomiR and commercial kits that are used in the miRNA data analysis are discussed in this article to provide extensive knowledge about the molecular diversity analysis of miRNA and their influences on cancerous cells.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.